Relief Therapeutics Holding AG (RLFTD) Stock Analysis
DELISTED 2023
What happened to Relief Therapeutics Holding AG (RLFTD) stock?
Relief Therapeutics Holding AG (RLFTD) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- July 2023
- Last recorded price (historical):
- $4.08 (last quote on record before the July 2023 delisting; historical, not a current quote)
Market cap $44.9M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Relief Therapeutics Holding AG (RLFTD). Relief Therapeutics Holding AG is a biopharmaceutical company focused on developing therapies for serious diseases with unmet medical needs.
Last analyzed: Mar 16, 2026Dated analysis: the newest financial statements on file are 28 months old (Jun 1, 2024), so the figures and score below describe that period, not today.
Relief Therapeutics Holding AG (RLFTD) Healthcare & Pipeline Overview
RLFTD OTC Market Information
RLFTD trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy RLFTD shares?
No. RLFTD stopped trading on public markets in July 2023, so the shares are not available through a broker. Anything you see quoted for RLFTD elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RLFTD stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Relief Therapeutics Holding AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.